ATEM ® Ipratropium bromide

ATEM ® is a drug based on Ipratropium bromide

THERAPEUTIC GROUP: Drugs for obstructive airway disorders

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ATEM ® Ipratropium bromide

ATEM ® is indicated in the treatment of obstructive airway disorders such as bronchial asthma and chronic obstructive pulmonary disease.

Mechanism of action ATEM ® Ipratropium bromide

Ipratropio bromide, the active ingredient of ATEM ®, is a quaternary derivative of atropine, used in the clinical setting for the treatment of obstructive airway disorders.

Once inhaled, it is able to interact with bronchial muscarinic receptors exerting a particularly rapid anticholinergic action in the onset timing.

The binding of Ipratropium bromide to the muscarinic m2 and M3 receptors expressed by the bronchial musculature, antagonizing the effect of acetylcholine, determines a bronchodilator action such as to improve the patency of the upper areas, restoring an adequate ventilatory flow that persists for about 4- 6 hours from hiring.

The low systemic absorption of the active ingredient also makes the therapy particularly safe, significantly limiting the risk of potential side effects.

Studies carried out and clinical efficacy

IPRATROPIO BROMURO AND RISK OF ARITHMIA

Pharmacotherapy. 2013 Aug 5. doi: 10.1002 / phar.1336. [Epub ahead of print]

Adimadhyam S, Schumock GT, Walton S, Joo M, McKell J, Lee TA.

Recent study demonstrating that the use of Ipratropium bromide may be associated with a greater risk of arrhythmia in patients with asthma aged between 12 and 14 years.

THE BROMUROUS IPRATROPIO FOR THE MUNICIPALITY OF THE COOLING INDUSTRY

Cochrane Database Syst Rev. 2013 Jun 19; 6: CD008231. doi: 10.1002 / 14651858.CD008231.pub3.

AlBalawi ZH, Othman SS, Alfaleh K.

Interesting work that demonstrates how the intranasal administration of Ipratropium bromide can determine a significant improvement of the rhinorrhea in patients suffering from common cold. Also this action would determine from the anticholinergic action of the active principle on the muciparous glands present in the nasal mucosa.

THE BROMUROUS IPRATROPIO IN ASSOCIATION WITH SALBUTAMOLO

Mymensingh Med J. 2013 Apr; 22 (2): 345-52.

Hossain AS, Barua UK, Roy GC, Sutradhar SR, Rahman I, Rahman G.

Work demonstrating that the association between Sulbutamol and Ipratropium bromide may present a more effective bronchodilator action than monotherapies, leading to a marked improvement in asthmatic symptoms

Method of use and dosage

ATEM ®

Aerosol dosed with 4 mg of Ipratropium bromide (20 mcg per inhalation)

Solution for aerosol use of 0.0250 grams of Ipratropium bromide.

Treatment with ATEM ® should be calibrated by your doctor based on the patient's clinical condition and his responsiveness to therapy.

Generally we recommend the application of 2 sprays 3 times a day or 1 ml for each aerosol session 1-2 times a day.

Warnings ATEM ® Ipratropium bromide

Treatment with ATEM ® should be defined and supervised by your doctor, considering the possible presence of contraindications to the use of this product and therefore its prescription appropriateness.

The patient should also carefully observe all the indications provided by the doctor, taking care to inform him promptly about the appearance of unwanted side effects rather than aggravations of the clinical picture.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the absence of studies able to characterize the safety profile of Ipratropium bromide for fetal and infant health, it would be appropriate to limit the use of ATEM ® during pregnancy and in the subsequent breastfeeding period, exclusively to cases of real need and always under the strict supervision of your doctor.

Interactions

Drug interactions worthy of clinical note are currently unknown.

Contraindications ATEM ® Ipratropium bromide

The use of ATEM ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, in patients suffering from glaucoma, prostatic hypertrophy or syndromes of urinary retention or intestinal obstruction.

Undesirable effects - Side effects

Therapy with ATEM ® is generally safe and well tolerated.

Adverse reactions such as dry mouth, dizziness, heart rhythm disturbances, constipation and urinary retention symptoms were only rarely observed, but immediately disappeared after the drug was suspended.